<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790243</url>
  </required_header>
  <id_info>
    <org_study_id>CL0006-01</org_study_id>
    <nct_id>NCT01790243</nct_id>
  </id_info>
  <brief_title>LEVANT 2 Safety Registry</brief_title>
  <official_title>A Prospective, Multicenter, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to
      evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus
      Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of stenosis or occlusion
      of the femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2011</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 27, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Unanticipated Device- or Drug-Related Serious Adverse Events at 60 Months Post Index Procedure.</measure>
    <time_frame>From index procedure to 60 months Post Index Procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Procedure</measure>
    <time_frame>30 days post index procedure</time_frame>
    <description>Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-Cause Perioperative (&lt;30 Day) Death, Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death at 1,6, 12, 24, 36, 48, and 60 Months Post Index Procedure</measure>
    <time_frame>1, 6, 12, 24, 36, 48, and 60 months post index procedure (PPI)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Patency of the Target Lesion at 6, 12, and 24 Months Post Index Procedure</measure>
    <time_frame>6, 12, and 24 months post index procedure</time_frame>
    <description>Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Device Success at Time of Index Procedure</measure>
    <time_frame>At time of index procedure</time_frame>
    <description>Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Technical and Procedural Success</measure>
    <time_frame>At time of index procedure</time_frame>
    <description>Technical Success is defined as successful access and deployment of the device and visual estimate of ≤30% diameter residual stenosis during the index procedure without deployment of a bailout stent.
Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Target Lesion Revascularization (TLR) at 6, 12, and 24 Months Post Index Procedure</measure>
    <time_frame>6, 12, and 24 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure</measure>
    <time_frame>6, 12, and 24 months post index procedure</time_frame>
    <description>Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) &lt;2.0 and &lt;3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline</measure>
    <time_frame>6, 12, and 24 months post index procedure</time_frame>
    <description>The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline</measure>
    <time_frame>6, 12, and 24 months from baseline</time_frame>
    <description>Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1189</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Femoropopliteal Artery Occlusion</condition>
  <condition>Femoropopliteal Stenosis</condition>
  <arm_group>
    <arm_group_label>Lutonix Drug Coated Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Uncoated Angioplasty Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix Drug Coated Balloon</intervention_name>
    <description>Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
    <arm_group_label>Lutonix Drug Coated Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA Balloon</intervention_name>
    <description>Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
    <arm_group_label>Standard Uncoated Angioplasty Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria:

          1. Male or non-pregnant female ≥18 years of age;

          2. Rutherford Clinical Category 2-4;

          3. Patient is willing to provide informed consent, is geographically stable and comply
             with the required follow up visits, testing schedule and medication regimen;

             Angiographic Lesion Inclusion Criteria:

          4. Length ≤15 cm;

          5. Up to two focal lesions or segments within the designated 15 cm length of vessel may
             be treated (e.g. two discrete segments, separated by several cm, but both falling
             within a composite length of &lt;15 cm);

          6. ≥70% stenosis by visual estimate;

          7. Lesion location starts ≥1 cm below the common femoral bifurcation and terminates
             distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the TP trunk;

          8. De novo lesion(s) or non-stented restenotic lesion(s) &gt;90 days from prior angioplasty
             procedure;

          9. Lesion is located at least 3 cm from any stent, if target vessel was previously
             stented;

         10. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available
             device size matrix;

         11. Successful, uncomplicated (without use of a crossing device) antegrade wire crossing
             of lesion;

         12. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by
             angiography (treatment of target lesion acceptable after successful treatment of
             inflow artery lesions); NOTE: Successful inflow artery treatment is defined as
             attainment of residual diameter stenosis ≤30% without death or major vascular
             complication.

         13. At least one patent native outflow artery to the ankle, free from significant (≥50%)
             stenosis as confirmed by angiography that has not previously been revascularized
             (treatment of outflow disease is NOT permitted during the index procedure);

         14. Contralateral limb lesion(s) cannot be treated within 2 weeks before and/or planned 30
             days after the protocol treatment in order to avoid confounding complications;

         15. No other prior vascular interventions within 2 weeks before and/or planned 30 days
             after the protocol treatment.

        Exclusion Criteria:

        Patients will be excluded if ANY of the following conditions apply:

          1. Pregnant or planning on becoming pregnant or men intending to father children;

          2. Life expectancy of &lt;5 years;

          3. Patient is currently participating in an investigational drug or other device study or
             previously enrolled in this study; NOTE: Enrollment in another clinical trial during
             the follow up period is not allowed.

          4. History of hemorrhagic stroke within 3 months;

          5. Previous or planned surgical or interventional procedure within 2 weeks before or
             within 30 days after the index procedure;

          6. History of MI, thrombolysis or angina within 2 weeks of enrollment;

          7. Rutherford Class 0, 1, 5 or 6;

          8. Renal failure or chronic kidney disease with MDRD GFR ≤30 ml/min per 1.73 m2 (or serum
             creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis);

          9. Prior vascular surgery of the index limb, with the exception of remote common femoral
             patch angioplasty separated by at least 2 cm from the target lesion;

         10. Inability to take required study medications or allergy to contrast that cannot be
             adequately managed with pre- and post-procedure medication;

         11. Anticipated use of IIb/IIIa inhibitor prior to randomization;

         12. Ipsilateral retrograde access;

         13. Composite lesion length is &gt;15 cm or there is no normal proximal arterial segment in
             which duplex flow velocity can be measured;

         14. Significant inflow disease. Successful treatment of inflow disease allowed prior to
             target lesion treatment;

         15. Known inadequate distal outflow (&gt;50 % stenosis of distal popliteal and/or all three
             tibial vessels), or planned future treatment of vascular disease distal to the target
             lesion;

         16. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target
             vessel;

         17. Severe calcification that renders the lesion un-dilatable;

         18. Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty,
             scoring/cutting balloon, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Rosenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mission Cardiovascular Research Institute</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic/St. Dominic's Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriHealth Heart Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>May 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2020</results_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01790243/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lutonix Drug Coated Balloon</title>
          <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
        </group>
        <group group_id="P2">
          <title>Standard Uncoated Angioplasty Balloon</title>
          <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1029"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="739"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lutonix Drug Coated Balloon</title>
          <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
        </group>
        <group group_id="B2">
          <title>Standard Uncoated Angioplasty Balloon</title>
          <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1029"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="1189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="9.7"/>
                    <measurement group_id="B2" value="69.0" spread="9"/>
                    <measurement group_id="B3" value="68.48" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="383"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="646"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="988"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="1134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Rutherford Classification</title>
          <description>Measure Description: Rutherford Classification is on an ascending scale from 0 to 6. Lower classifications on the scale indicate more favorable outcomes.
0- Asymptomatic
Mild claudication
Moderate claudication
Severe claudication
Rest pain
Ischemic ulceration not exceeding ulcer of the digits of the foot
Severe ischemic ulcers or frank gangrene</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Rutherford 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="409"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="606"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="698"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford 5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rutherford 6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unanticipated Device- or Drug-Related Serious Adverse Events at 60 Months Post Index Procedure.</title>
        <time_frame>From index procedure to 60 months Post Index Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unanticipated Device- or Drug-Related Serious Adverse Events at 60 Months Post Index Procedure.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Procedure</title>
        <description>Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint)</description>
        <time_frame>30 days post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Procedure</title>
          <description>Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint)</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1002"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-Cause Perioperative (&lt;30 Day) Death, Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death at 1,6, 12, 24, 36, 48, and 60 Months Post Index Procedure</title>
        <time_frame>1, 6, 12, 24, 36, 48, and 60 months post index procedure (PPI)</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-Cause Perioperative (&lt;30 Day) Death, Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death at 1,6, 12, 24, 36, 48, and 60 Months Post Index Procedure</title>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1010"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death : 1 month post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1009"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death : 6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="990"/>
                    <count group_id="O2" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death : 12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="967"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death : 24 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="927"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death : 36 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="912"/>
                    <count group_id="O2" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death : 48 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="901"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death : 60 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="879"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 1 month post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1008"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="982"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="955"/>
                    <count group_id="O2" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 24 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="890"/>
                    <count group_id="O2" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 36 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 48 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="791"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Amputation : 60 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="740"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 1 month post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1008"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="981"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="954"/>
                    <count group_id="O2" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 24 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="888"/>
                    <count group_id="O2" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 36 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 48 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="790"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Amputation : 60 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="737"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 1 month PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1009"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1008"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="989"/>
                    <count group_id="O2" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="981"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 12 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="967"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 24 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="928"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 36 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="913"/>
                    <count group_id="O2" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 48 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="901"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation Free Survival : 60 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="881"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 1 month PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1008"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 6 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="981"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 12 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="955"/>
                    <count group_id="O2" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 24 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="898"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 36 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="857"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 48 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="820"/>
                    <count group_id="O2" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Vessel Revascularization : 60 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="780"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis : 1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1008"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis : 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="981"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis : 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="954"/>
                    <count group_id="O2" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis : 24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="888"/>
                    <count group_id="O2" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis: 36 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis : 48 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reintervention for thrombosis: 60 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="738"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 1 month PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1009"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 6 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="983"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 12 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="957"/>
                    <count group_id="O2" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 24 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="900"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 36 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="858"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 48 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="812"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Hospitalization : 60 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="768"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 1 month PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1010"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 6 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="985"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 12 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="958"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 24 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="902"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 36 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="861"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 48 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="821"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complications : 60 months PPI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="776"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Patency of the Target Lesion at 6, 12, and 24 Months Post Index Procedure</title>
        <description>Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).</description>
        <time_frame>6, 12, and 24 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Patency of the Target Lesion at 6, 12, and 24 Months Post Index Procedure</title>
          <description>Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="916"/>
                    <count group_id="O2" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="78.9" upper_limit="84.0"/>
                    <measurement group_id="O2" value="64.8" lower_limit="56.9" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="897"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="63.2" upper_limit="69.4"/>
                    <measurement group_id="O2" value="54.0" lower_limit="45.7" upper_limit="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="51.1" upper_limit="57.8"/>
                    <measurement group_id="O2" value="47.2" lower_limit="38.6" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Acute Device Success at Time of Index Procedure</title>
        <description>Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.</description>
        <time_frame>At time of index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Device Success at Time of Index Procedure</title>
          <description>Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.</description>
          <units>Devices</units>
          <param>Count of Units</param>
          <units_analyzed>Devices</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1404"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1402"/>
                    <measurement group_id="O2" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Technical and Procedural Success</title>
        <description>Technical Success is defined as successful access and deployment of the device and visual estimate of ≤30% diameter residual stenosis during the index procedure without deployment of a bailout stent.
Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.</description>
        <time_frame>At time of index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Technical and Procedural Success</title>
          <description>Technical Success is defined as successful access and deployment of the device and visual estimate of ≤30% diameter residual stenosis during the index procedure without deployment of a bailout stent.
Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1016"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Technical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="894"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Procedural Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="892"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Target Lesion Revascularization (TLR) at 6, 12, and 24 Months Post Index Procedure</title>
        <time_frame>6, 12, and 24 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Target Lesion Revascularization (TLR) at 6, 12, and 24 Months Post Index Procedure</title>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="981"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="940"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="955"/>
                    <count group_id="O2" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Months Post-Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="898"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure</title>
        <description>Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) &lt;2.0 and &lt;3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase.</description>
        <time_frame>6, 12, and 24 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure</title>
          <description>Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) &lt;2.0 and &lt;3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="792"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DUS PSVR &gt;=2.0: 6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="790"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DUS PSVR &gt;=2.0: 12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="762"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DUS PSVR &gt;=2.0: 24 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="716"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DUS PSVR &gt;=3.0: 6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="792"/>
                    <count group_id="O2" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DUS PSVR &gt;=3.0: 12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="743"/>
                    <count group_id="O2" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DUS PSVR &gt;=3.0: 24 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="671"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline</title>
        <description>The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.</description>
        <time_frame>6, 12, and 24 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline</title>
          <description>The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="944"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="830"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="890"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="771"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="816"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="701"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline</title>
        <description>Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.</description>
        <time_frame>6, 12, and 24 months from baseline</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix Drug Coated Balloon</title>
            <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
          <group group_id="O2">
            <title>Standard Uncoated Angioplasty Balloon</title>
            <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline</title>
          <description>Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="892"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="892"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.26"/>
                    <measurement group_id="O2" value="0.16" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="845"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.26"/>
                    <measurement group_id="O2" value="0.18" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Months Post-Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="753"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.27"/>
                    <measurement group_id="O2" value="0.17" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and Serious Adverse Events (SAEs) collected by all sites from the time of index procedure to 60 months follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lutonix Drug Coated Balloon</title>
          <description>Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
Lutonix Drug Coated Balloon: Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
        </group>
        <group group_id="E2">
          <title>Standard Uncoated Angioplasty Balloon</title>
          <description>PTA Catheter
Standard PTA Balloon: Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="813" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus, Type I</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus, Type II</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperthroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypothroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Endocrine system</sub_title>
                <description>These SAEs are not broken down further in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Colon carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other infections / inflammatory</sub_title>
                <description>Category of SAE not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other infectious / inflammatory</sub_title>
                <description>Category of SAE not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Gastrointestinal</sub_title>
                <description>Category of SAE not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusion puncture site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hematoma / bleeding puncture site - major</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hematoma / bleeding puncture site - minor</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pseudo aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Puncture site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vascular perforation / rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Retroperitoneal bleed</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Significant blood loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Access site complication</sub_title>
                <description>This category of SAEs is not broken down further in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Allergy</sub_title>
                <description>SAE entered as part of a Category titled &quot;Systematic Complication&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anaphylatic reaction</sub_title>
                <description>SAE entered as part of a Category titled &quot;Systematic Complication&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Systematic complication</sub_title>
                <description>Category of SAE not further broken down in Clinical Study Report. SAE entered as part of a Category titled &quot;Systematic Complication&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atherosclerosis</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Occlusion / closure</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombus - in-lesion</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Target vessel</sub_title>
                <description>This SAE was entered in &quot;Target Vessel&quot; category in Clinical Study Report. SAE not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Amputation</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atypical chest pain</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Carcinoma (not specified elsewhere)</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Death (non-cardiac or neurological)</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>SAE entered in a category titled &quot;Various&quot; in the Clinical Study Report. Therefore, the SAE is hereby classified under &quot;General Disorder&quot; Organ System category. SAE &quot;other&quot; is not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arterial occlusion</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atherosclerosis</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hematoma / bleeding</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stent thrombosis (definite)</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stent thrombosis (possible)</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Vessel Specific</sub_title>
                <description>SAE entered in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot; in Clinical Study Report.
SAE not otherwise broken down in the Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Local infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Septicemia / bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Infectious</sub_title>
                <description>Category of SAE not otherwise broken down in the Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Category &quot;Skeletal, Spine and Muscular System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fracture (bone)</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Skeletal, spine and muscular system</sub_title>
                <description>Category of SAE not otherwise broken down in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dizziness / vertigo</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fainting / syncope</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peripheral nervous system complication</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stroke - hemorrhagic</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stroke - ischemic</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>TIA</sub_title>
                <description>Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Neurological / nervous system</sub_title>
                <description>Category of SAE not otherwise broken down in the Clinical Study Report. Category &quot;Neurological/Nervous System&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Kidney stones</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Prostate carcinoma</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Prostate hypertrophy</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Renal failure / insufficiency</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary infection</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Genito-urinary system</sub_title>
                <description>SAE part of a category titled &quot;Genito-urinary&quot; in Clinical Study report. SAE entry not otherwise broken down in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other respiratory</sub_title>
                <description>Category of SAE not otherwise broken down in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Angina, stable</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Angina, unstable</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bradycardia</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Tachycardia</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Other</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report. This category is not broken down further in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chronic heart failure</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Cardiovascular</sub_title>
                <description>Category &quot;Cardiovascular&quot; in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="845" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina, Stable</sub_title>
                <description>AE entered in category &quot;Cardiovascular&quot; in clinical Study report.</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Other</sub_title>
                <description>AE entered in category &quot;Cardiovascular&quot; in clinical Study report. AE (other) not otherwise broken down in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>AE entered in category &quot;Cardiovascular&quot; in clinical Study report.</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>AE entered in category &quot;Cardiovascular&quot; in clinical Study report.</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Cardiovascular</sub_title>
                <description>AE entered in category &quot;Cardiovascular&quot; in clinical Study report. AE &quot;Other&quot; not otherwise broken down in the Clinical Study report.</description>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus, Type II</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Endocrine system</sub_title>
                <description>AE (Other) not otherwise broken down in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Gastrointestinal</sub_title>
                <description>AE (other) not otherwise broken down in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma / bleeding puncture site - minor</sub_title>
                <description>AE entered in category &quot;Access Site Complication&quot; in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <description>AE entered in &quot;Target Lesion&quot; Category of Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Genito-urinary system</sub_title>
                <description>AE (Other) not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>AE reported in category &quot;Various&quot; in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>AE &quot;Other&quot; not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="399" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <description>AE reported in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot;in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <description>AE reported in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot;in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Vessel Specific</sub_title>
                <description>AE reported in category &quot;Vessel specific complications in the leg (not target lesion or target vessel)&quot;in the Clinical Study Report.
AE (Other) not otherwise broken down in clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Local infection</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other infectious</sub_title>
                <description>AE (Other) not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fracture (bone)</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other skeletal, spine and muscular system</sub_title>
                <description>AE (Other) not otherwise broken down in Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="272" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness / vertigo</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other Neurological / nervous system</sub_title>
                <description>AE (Other) not otherwise broken down in the Clinical Study Report.</description>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure / insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary infection</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Other respiratory</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1029"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Lovas</name_or_title>
      <organization>Becton Dickinson</organization>
      <phone>7634452382</phone>
      <email>anna.lovas@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

